PKPriya Kohli

Priya Kohli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Priya Kohli has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Novel and Established Neuroimaging Modalities in Neurogenic Lower Urinary Tract Dysfunction

    by Nhi Ha, Mohammad Z. Khan, Priya Kohli, Petr Gaburak, Yusen Wang, Aidin Abedi, Evgeniy Kreydin

    Purpose of Review: Neurogenic lower urinary tract dysfunction (NLUTD) is a condition characterized by bladder or urinary sphincter control issues due to neurologic dysregulation. NLUTD commonly causes symptoms like urinary incontinence and retention that impact both urinary health and quality of life. Current NLUTD treatment primarily manages symptoms, as restorative interventions are limited by a lack of diagnostic approaches to understand its underlying neurologic mechanisms. Neuroimaging may help identify neurologic pathways associated with bladder control, providing insights into functional and structural neural changes in NLUTD. This report reviews current neuroimaging modalities and their efficacy in detecting NLUTD. Recent Findings: Evaluated modalities include functional magnetic resonance imaging, positron emission tomography, functional near-infrared spectroscopy, functional ultrasonography, electrocorticography, and deep brain stimulation. Each modality’s unique characteristics, such as resolution and invasiveness, shape its application in studying neurologic mechanisms of NLUTD. Collectively, they reveal a consistent finding: reduced brain activation in circuits related to bladder voiding and storage in patients with NLUTD. Summary: By examining each method’s mechanism, effectiveness, advantages, and limitations, we aim to aid clinicians and researchers in selecting the best techniques for exploring the mechanisms of NLUTD and developing restorative treatments.


  • Resilience as an Independent Predictor of Bowel Related Quality of Life After Spinal Cord Injury

    by Aidin Abedi, Stefania Montero, Luis Alejandro Morales Ojeda, Petr Gaburak, Priya Kohli, Armita Abedi, David Chapman, David Ginsberg, Evgeniy Kreydin

    Bowel dysfunction remains a prominent priority in the rehabilitation of patients with spinal cord injuries (SCIs). However, our understanding of the factors that influence bowel-related quality of life (QoL) in this population remains limited. This study aimed to investigate the potential role of resilience, defined as an individual's capacity to cope with and adapt to adversity, as a predictor of bowel-related QoL among the patients with SCI. A cohort of adult patients with SCI who received bowel and bladder care at an outpatient clinic within a large rehabilitation hospital was identified through a prospectively collected database. Resilience was measured using the Spinal Cord Injury-Quality of Life (SCI-QOL) Resilience Short Form, whereas bowel QoL was assessed using the Irritable Bowel Syndrome-Quality of Life (IBS-QoL) questionnaire. Univariate and multivariate regression analyses were employed to identify predictors of bowel-related QoL. The examined variables included age, gender, level and completeness of injury, time since injury, hand function, resilience, and the severity of bowel dysfunction as measured using the Neurogenic Bowel Dysfunction Score (NBDS). A total of 73 patients participated in this study, with a mean age of 44.01 ± 13.43 years and comprising mostly men ( n = 57, 78%). The results revealed a significant correlation between resilience scores and the total score of IBS-QoL ( ρ = -0.47, p < 0.0001). The multivariate analysis demonstrated that both resilience and the severity of bowel dysfunction were significant independent predictors of bowel-related QoL, with resilience demonstrating a stronger association. Overall, this study elucidates the importance of resilience in shaping patients' perceptions of their bowel health within the SCI population. In addition to the more expected determinants of bowel-related QoL, such as the severity of bowel dysfunction, resilience emerged as a notable factor. Accordingly, integrating interventions that enhance resilience within bowel rehabilitation programs may yield improvements in patients' perceived bowel health beyond the benefits achievable through bowel function enhancement alone.


  • Open Access

    Noninvasive spinal neuromodulation mitigates symptoms of idiopathic overactive bladder

    by Hui Zhong, Emilie Liu, Priya Kohli, Laura Perez, V. Reggie Edgerton, David Ginsberg, Parag Gad, Evgeniy Kreydin

    Background: Overactive bladder (OAB) affects 12 to 30% of the world’s population. The accompanying urinary urgency, frequency and incontinence can have a profound effect on quality of life, leading to depression, social isolation, avoidance of sexual activity and loss of productivity. Conservative measures such as lifestyle modification and pelvic floor physical therapy are the first line of treatment for overactive bladder. Patients who fail these may go on to take medications, undergo neuromodulation or receive injection of botulinum toxin into the bladder wall. While effective, medications have side effects and suffer from poor adherence. Neuromodulation and botulinum toxin injection are also effective but are invasive and not acceptable to some patients. Methods: We have developed a novel transcutaneous spinal cord neuromodulator (SCONE™,) that delivers multifrequency electrical stimulation to the spinal cord without the need for insertion or implantation of stimulating electrodes. Previously, multifrequency transcutaneous stimulation has been demonstrated to penetrate to the spinal cord and lead to motor activation of detrusor and external urethral sphincter muscles. Here, we report on eight patients with idiopathic overactive bladder, who underwent 12 weeks of SCONE™ therapy. Results: All patients reported statistically significant clinical improvement in multiple symptoms of overactive bladder, such as urinary urgency, frequency and urge incontinence. In addition, patients reported significant symptomatic improvements as captured by validated clinical surveys. Conclusion: SCONE™ therapy represents the first of its kind therapy to treat symptoms of urgency, frequency and urge urinary incontinence in patients with OAB. Trial registration: The study was listed on clinicaltrials.gov (NCT03753750).


  • Vesicouterine Fistula

    by Atieh Novin, Priya Kohli, Evgeniy Kreydin, Janine Oliver